Longwood Fund and seasoned leaders in CNS drug development
Company Description
Newleos Therapeutics is a clinical stage neuroscience company focused on developing oral small molecules targeting novel mechanisms for various CNS indications including generalized anxiety, social anxiety, substance use disorders, and cognitive impairment.
Market
CNS drug development
Location
Boston,
MA,
USA
Coinvestors
Goldman Sachs Alternatives, Novo Holdings A/S, Longwood Fund, DCVC Bio, Arkin Bio Capital